Skip to main content

Table 4 Treatment of persons with epilepsy from four different studies

From: Characteristics of people with epilepsy in three Eastern African countries – a pooled analysis

   Tanzania (Dar es Salaam) Tanzania (Haydom) Malawi Uganda
N   302 212 365 300
 ASM   270 (89.7) 209 (98.6) 248 (67.9) 233 (77.7)
 ASM type monotherapy 243/268 (90.7) 209/209 (100) 222/229 (96.9) 233/233 (100)
 carbamazepine 134/268 (50.0) 156/209 (74.6) 7/229 (3.1) 31/233 (13.3)
 phenobarbital 103/268 (38.4) 53/209 (25.4) 201/229 (87.8) 55/233 (23.6)
 phenytoin 2/268 (0.7) 0/209 14/229 (6.1) 147/233 (63.1)
 valproic acid 4/268 (1.5) 0/209 0/229 0/233
combination therapy 25/268 (9.3) 0/209 7/229 (3.1) 0/233
 carbamazepine, phenobarbital 13/268 (4.9) 0/209 0/229 0/233
 carbamazepine, phenytoin 4/268 (1.5) 0/209 2/229 (0.9) 0/233
 carbamazepine, valproic acid 1/268 (0.4) 0/209 0/229 0/233
 phenobarbital, gabapentin 1/268 (0.4) 0/209 0/229 0/233
 phenobarbital, phenytoin 6/268 (2.2) 0/209 5/229 (2.2) 0/233
missing/unknown 2 0 19 0
Ever treated with other ASM 78 (27.2) NA NA 31 (10.3)
 Reason for changing ASM no response 9/24 (37.5) NA NA 17/31 (54.8)
side effects 8/24 (33.3) NA NA 0/31
stock-out 2/24 (8.3) NA NA 5/31 (16.1)
other 5/24 (20.8) NA NA 9/31 (29.0)
missing 54 NA NA 0
Herbal treatment   159 (53.5) 105 (49.5) 304 (83.2) 108 (36.0)
Scarification   56 (19.2) 43 (20.3) 33 (9.0) 10 (3.3)
  1. ASM Anti-seizure medication